Press release
Health Care
March 2, 2021

Evonik recognized as a leading contract manufacturing organization for the pharmaceutical industry for the fourth year in a row

  • Evonik recognized a 2021 CMO Leadership Awards winner
  • Evonik wins awards in all six categories - Capabilities, Compatibility, Expertise, Quality, Reliability and Service
  • Voted by pharmaceutical companies as a leading CMO partner for the fourth year running

Essen, Germany. Evonik, one of the world’s largest contract development and manufacturing organizations (CDMO) for active pharmaceutical ingredients (APIs) and advanced intermediates, has been recognized as a recipient of the 2021 CMO Leadership Awards across all six categories for the fourth year running.

Winners are chosen through market research based on feedback from pharmaceutical companies that utilize outsourcing services. Evonik’s success confirms the company’s outstanding performance and value to the pharmaceutical and life science industries.

As one of the world’s top CMOs for active pharmaceutical ingredients and intermediates, the Health Care business line is part of the life science division Nutrition & Care and represents a key growth lever for Evonik. To meet growing customer demand for its CMO services, Evonik is expanding its production capacity at two sites in Germany, as announced in May 2020.

“To be recognized by our customers as a leader for the fourth time in a row is a tremendous honor,” said Thomas Riermeier, head of Evonik’s Health Care business line. “This award further validates our position as a preferred development and manufacturing partner for pharmaceutical, biotech and life science companies.”

Life Science Leader magazine and Outsourced Pharma teamed up with Industry Standard Research (ISR) to assess more than 70 CMOs across 23 performance metrics as part of ISR’s 2021 Contract Manufacturing Quality Benchmarking survey of global pharmaceutical and biotechnology companies. For the fourth consecutive year, participating companies voted for Evonik to earn awards for its Capabilities, Compatibility, Expertise, Quality, Reliability and Service.

“We are grateful for the trust our customers place in us every day to manufacture their life-saving active pharmaceutical ingredients and intermediates”, said Andreas Meudt, head of product line Exclusive Synthesis at Evonik Health Care. “We are committed to continuously expanding our Western-based manufacturing network as well as our portfolio of advanced technologies to maximize supply security and product quality.”

To address the specific needs of large or complex projects, Evonik has established a broad portfolio of advanced technologies which can be combined to support multi-step API synthesis. These technologies include continuous processes, fermentation, PEGs and mPEGs, catalysts, biocatalysts, cryogenic chemistry and polymer APIs.

For many specialized therapy areas, Evonik serves as a fully integrated CMO with capabilities to manufacture customized APIs, select and supply functional excipients, develop parenteral or oral formulations, and manufacture finished drug products. In addition to this integrated portfolio of services, many customers are also attracted by Evonik’s reliability and commitment to sustainability.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €13.1 billion and an operating profit (adjusted EBITDA) of €2.15 billion in 2019. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 32,000 employees work together for a common purpose: We want to improve life, today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around €2.9 billion in 2019 with about 5,300 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Explore more